S14 Ep4: FDA Approval Insights: Dordaviprone in H3K27M-Mutated Diffuse Midline Glioma: With Patrick Y. Wen, MD

OncLive® On Air - Un pódcast de OncLive® On Air

prueba podimo gratis durante 60 días!

Miles de audiolibros y podcasts exclusivos, haz clic aquí para probar

Dr Wen discussed the significance of the FDA approval of dordaviprone for patients at least 1 year of age with H3K27M-mutated diffuse midline glioma.